Q3 2019 BeyondSpring Inc Earnings Call

18/12/2019 8:00

שיחת ועידה BeyondSpring Inc

BeyondSpring Inc Conference call will be held on 18/12/2019. During the earnings conference call's session BeyondSpring Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact BeyondSpring Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. We are advancing our lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia, a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC. Plinabulin has also entered the first of a number of planned Phase 1/2 clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. In addition, we are developing three preclinical agents internally and up to six new agents a year for the next five years through our research collaborations. Plinabulin is a marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities.    
קרא עוד שיחת ועידה

BeyondSpring Inc (BYSI)

28 Liberty Street, New York New York 10005, United States